IGF Oncology LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.igfoncology.com
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
Phase 1
Terminated
- Conditions
- Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicAnemia, Refractory, With Excess of Blasts
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- IGF Oncology, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT03175978
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Regions Cancer Care Center, Saint Paul, Minnesota, United States
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
Phase 1
Completed
- Conditions
- Brain CancerGynecologic CancersMelanomaGastrointestinal CancersThoracic CancersBreast CancerGenitourinary CancersHead and Neck Cancers
- Interventions
- Drug: IGF-Methotrexate conjugate
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- IGF Oncology, LLC
- Target Recruit Count
- 92
- Registration Number
- NCT02045368
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath